Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)Antonio Avallone, Maria Carmela Piccirillo, Gerardo Rosati et al.|Annals of Oncology|2018Cited by 0